Advanced search
Publication Cover
Molecular & Cellular Oncology Volume 1, 2014 - Issue 3
Submit an article Journal homepage
1,976
Views
8
CrossRef citations to date
0
Altmetric
Reviews

Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment

Pau CastelHuman Oncology & Pathogenesis Program (HOPP); Memorial Sloan Kettering Cancer Center; New York, NYUSA
,
Eneda ToskaHuman Oncology & Pathogenesis Program (HOPP); Memorial Sloan Kettering Cancer Center; New York, NYUSA
,
Zachary S ZumstegHuman Oncology & Pathogenesis Program (HOPP); Memorial Sloan Kettering Cancer Center; New York, NYUSA
,
F Javier CarmonaHuman Oncology & Pathogenesis Program (HOPP); Memorial Sloan Kettering Cancer Center; New York, NYUSA
,
Moshe ElkabetsHuman Oncology & Pathogenesis Program (HOPP); Memorial Sloan Kettering Cancer Center; New York, NYUSA
,
Ana BoschHuman Oncology & Pathogenesis Program (HOPP); Memorial Sloan Kettering Cancer Center; New York, NYUSA
&
Maurizio ScaltritiHuman Oncology & Pathogenesis Program (HOPP); Memorial Sloan Kettering Cancer Center; New York, NYUSACorrespondence[email protected]
 show all
Article: e963447 | Received 17 Jun 2014, Accepted 12 Aug 2014, Published online: 23 Dec 2014

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Akshay Pratap, Andrea Qualman, Hedlund Garrett, Lindsey Westbrook, Erlinda The, Sanchayita Mitra, Mila Cordero, Kenneth Meza Monge, Juan- Pablo Idrovo, Argudit Chauhan, Linling Cheng, Mitchell Jay Cohen, Benedetto Mungo, Sachin Wani, Robert Alexander Meguid, Martin D McCarter & Xianzhong Meng. (2023) Silencing Glypican-1 enhances the antitumor effects of Pictilisib via downregulating PI3K/Akt/ERK signaling in chemo-resistant esophageal adenocarcinoma. Molecular & Cellular Oncology 10:1.
Read now

Articles from other publishers (7)

Jingyi Li. (2023) Nutrient Metabolisms in Cancer and Related Signaling Pathways. Highlights in Science, Engineering and Technology 36, pages 1318-1327.
Crossref
Fan Chen, Jinpeng Liu, Xiulong Song, Tanner J. DuCote, Aria L. Byrd, Chi Wang & Christine F. Brainson. (2022) EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition. Cancer Letters 524, pages 151-160.
Crossref
Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Philippe L. Bedard, Jasgit C. Sachdev, Lara Dunn, Helen Won, John Bond, Surai Jones, Heidi M. Savage, Maurizio Scaltriti, Timothy R. Wilson, Michael C. Wei & David M. Hyman. (2021) Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers . Clinical Cancer Research 27:2, pages 447-459.
Crossref
Xi Ou, Guang-tao Zhang, Zhe Xu, Jing-sen Chen, Yong Xie, Ji-Kui Liu & Xiao-Ping Liu. (2018) Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway. Pathology & Oncology Research 25:2, pages 635-646.
Crossref
Maria Li Lung, Wei Dai & Josephine Mun-Yee Ko. 2019. Nasopharyngeal Carcinoma. Nasopharyngeal Carcinoma 17 44 .
Kadirappa Aggile, Manikandan Alagumuthu, Reddy Sailaja Mundre & Ayyakannu Arumugam Napoleon. (2018) Synthesis of Substituted Quinolinyl Ether-based Inhibitors of PI3K as Potential Anticancer Agents. Journal of Heterocyclic Chemistry 55:7, pages 1669-1677.
Crossref
Yi Yu, Terence Hall, Sudharshan Eathiraj, Michael J. Wick, Brian Schwartz & Giovanni Abbadessa. (2017) In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. Anti-Cancer Drugs 28:5, pages 503-513.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.